Publicación: COVID-19 Vaccines, Healthcare Policies and Stock Markets: Are There Winners and Losers?
Fecha
2023-05-24
Editor/a
Director/a
Tutor/a
Coordinador/a
Prologuista
Revisor/a
Ilustrador/a
Derechos de acceso
info:eu-repo/semantics/openAccess
Título de la revista
ISSN de la revista
Título del volumen
Editor
Taylor and Francis Group
Resumen
Purpose: This paper focuses on the stock market performance of a set of biopharmaceutical companies listed in the US stock exchange in response to news about the unfolding of the COVID pandemic and the development of COVID-19 vaccines.
Methods: We analyze the short-term impact of some episodes by means of event analysis. We consider two categories of events: news related to the expansion of the pandemic and information about the development of COVID-19 vaccines.
Results: We find that the impact during the first months of the pandemic news impacted the returns of the pharmaceutical firms, but the effect was not large, in general. The only exceptions are two small biotechnological firms, Moderna and Novavax, are exceptions since they registered large positive abnormal returns, which vanished over time. Encouraging announcements about the success of Phase III results had a positive impact the share prices of Pfizer, Moderna and Novavax. Our results also suggest that the emergency authorization provided by the US regulatory agency to the Pfizer vaccine was anticipated several days in advance and welcomed by the market. The announcement of a deal to supply vaccines between Moderna and the European Commission have generated large positive returns for this company.
Conclusion: Our findings have policy implications. First, financial markets have supported and reinforced government strategies to fight the pandemic, characterized by funding of promising projects, building diversified vaccine portfolios and expediting approvals by regulatory agencies. Second, our findings suggest that not all drug developers have automatically obtained large profits from the design and manufacturing of COVID-19 vaccines, according to the behaviour of stock prices. These results cast doubts over attempts to discredit the efficacy of COVID-19 vaccines with the argument that they are primarily a means to obtain large and quick profits by pharmaceuticals, or than vaccination campaigns are driven by economic goals rather than by public health considerations.
Descripción
La versión registrada de este artículo, publicado por primera vez en Risk Manag Healthc Policy. 2023;16:971-989, está disponible en línea en el sitio web del editor: https://doi.org/10.2147/RMHP.S406216
The recorded version of this article, first published in Risk Management Healthc Policy. 2023; 16:971-989, available online at the publisher's website: https://doi.org/10.2147/RMHP.S406216
Categorías UNESCO
Palabras clave
event analysis, COVID-19 vaccines, phase III, clinical trials, pharmaceutical industry, stock markets
Citación
Diaz RF, Herrador-Alcaide TC, Sanchez-Robles B. COVID-19 Vaccines, Healthcare Policies and Stock Markets: Are There Winners and Losers?. Risk Manag Healthc Policy. 2023;16:971-989 https://doi.org/10.2147/RMHP.S406216
Centro
Facultad de Ciencias Económicas y Empresariales
Departamento
Análisis Económico